Danish pharmaceutical company Novo Nordisk tackles both obesity and diabetes in their current drug pipeline.
Being overweight or obese has long been known to be a risk factor for type 2 diabetes.
Danish pharmaceutical company Novo Nordisk tackles both obesity and diabetes in their current drug pipeline.
Being overweight or obese has long been known to be a risk factor for type 2 diabetes.